CASI Pharmaceuticals has entered into an exclusive distribution agreement, whereby under the terms of the agreement, China Resources Guokang Pharmaceuticals will be the sole distributor for the sale of melphalan hydrochloride for injection – Evomela – in China. Melphalan hydrochloride for injection, Evomela, was previously granted priority review by the National Medical Products Administration and subsequently approved for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma, and the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. The estimated incidence of multiple myeloma in China is ~2.0 cases per 100,000 persons, for an estimated annual incidence of approximately 27,800.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.